Dasatinib sandoz

Package leaflet: Information for the patient

Dasatinib Sandoz, 140 mg, film-coated tablets
Dasatinibum
Read the entire leaflet carefully before using the medicine, because it contains
important information for the patient.

• Keep this leaflet, as you may need to read it again.
• If you have any further questions, please consult your doctor or pharmacist.
• This medicine has been prescribed for a specific individual. Do not pass it on to others. The medicine may harm another person, even if their symptoms are the same.
• If you experience any adverse reactions, including any not listed in this leaflet, inform your doctor or pharmacist immediately. See section 4.

Table of contents

1. What Dasatinib Sandoz is and what it is used for
2. Important information before taking Dasatinib Sandoz
3. How to take Dasatinib Sandoz
4. Possible side effects
5. How to store Dasatinib Sandoz
6. Contents of the pack and other information

1. What Dasatinib Sandoz is and what it is used for

Dasatinib Sandoz contains the active substance dasatinib. This medicine is used to treat chronic
myeloid leukaemia (CML) in adults, adolescents and children aged at least 1 year. Leukaemia
is a cancer of the white blood cells – blood cells that normally help the body fight infections.
In people with chronic myeloid leukaemia, the number of white blood cells increases in an
uncontrolled manner. Dasatinib Sandoz inhibits the growth of these leukaemic cells.
Dasatinib Sandoz is also used to treat Philadelphia chromosome-positive (Ph+) acute
lymphoblastic leukaemia (ALL) and the lymphoblastic blast crisis phase of CML in adults,
adolescents and children aged at least 1 year, when previous treatment has been ineffective.
In people with acute lymphoblastic leukaemia, white blood cells called lymphocytes multiply too
quickly and live too long. Dasatinib Sandoz inhibits the growth of these leukaemic cells.
If you have any questions about how Dasatinib Sandoz works or why it was prescribed for you,
please consult your doctor.

2. Important information before using Dasatinib Sandoz

When not to use Dasatinib Sandoz

• if the patient is allergic to dasatinib or to any of the other ingredients of this medicine (listed in section 6).

If you suspect an allergic reaction, consult a doctor.
Warnings and precautions
Before taking (or while using) Dasatinib Sandoz, discuss with your doctor or pharmacist if:

• the patient is taking medicines to thin the blood or prevent blood clots (see "Dasatinib Sandoz and other medicines");
• the patient has or has had liver or heart problems;
• the patient experiences difficulty breathing, chest pain or cough during treatment: these may be symptoms of fluid retention in the lungs or chest cavity (which may be more common in patients aged 65 years or older), or symptoms caused by changes in blood vessels supplying the lungs;
• the patient has had or may currently have hepatitis B virus infection (dasatinib may cause reactivation of hepatitis B virus, which in some cases may be fatal). Before starting treatment, the doctor will carefully check whether the patient shows signs of this infection;
• the patient develops bruising, bleeding, fever, fatigue or confusion during treatment with Dasatinib Sandoz. Contact the doctor immediately, as these may be symptoms of blood vessel damage, known as thrombotic microangiopathy.

The doctor will regularly monitor the patient's condition to assess whether dasatinib is having the desired effect. While taking Dasatinib Sandoz, the patient will also undergo regular blood tests.

Children and adolescents
This medicine must not be given to children under 1 year of age. Experience with dasatinib in this age group is limited. In children treated with dasatinib, bone growth and development should be closely monitored.

Dasatinib Sandoz and other medicines
Tell your doctor about all medicines the patient is currently taking or has recently taken, as well as any medicines the patient plans to take.

Dasatinib is mainly metabolized in the liver. Some concomitant medicines may interfere with its action.

The following medicines should not be taken together with Dasatinib Sandoz:

• ketoconazole, itraconazole – antifungal medicines
• erythromycin, clarithromycin, telithromycin – antibiotics
• ritonavir – antiviral medicine
• phenytoin, carbamazepine, phenobarbital – medicines used to treat epilepsy
• rifampicin – medicine used to treat tuberculosis
• famotidine, omeprazole – medicines that reduce gastric acid secretion
• St John's wort (Hypericum perforatum) – a herbal remedy available without prescription, used to treat depression and other conditions.

Do not take medicines that neutralize gastric acid (such as those containing aluminium hydroxide or magnesium hydroxide) within 2 hours before or 2 hours after taking Dasatinib Sandoz.

Tell your doctor if the patient is taking blood-thinning medicines or medicines to prevent blood clots.

Dasatinib Sandoz with food and drink
Do not take Dasatinib Sandoz with grapefruit or grapefruit juice.

Pregnancy and breastfeeding
If the patient is pregnant or suspects she may be pregnant, she should inform the doctor immediately. Dasatinib Sandoz must not be used during pregnancy, unless absolutely necessary. The doctor will discuss with the patient the potential risks associated with using dasatinib during pregnancy.

Both men and women receiving Dasatinib Sandoz are advised to use effective contraception during treatment.

If a woman is breastfeeding, she should inform her doctor. Breastfeeding must not be continued while taking Dasatinib Sandoz.

Driving and using machines
If the patient experiences adverse effects such as dizziness or blurred vision, extreme caution should be exercised when driving or operating machinery.

Dasatinib Sandoz contains lactose and sodium
If the patient has previously been diagnosed with intolerance to certain sugars, this should be reported to the doctor before taking the medicine.

This medicine contains less than 1 mmol (23 mg) of sodium per dose unit, meaning the medicine is considered "sodium-free".

3. How to use Dasatinib Sandoz

Dasatinib Sandoz should only be prescribed by a physician experienced in the treatment of leukemia. This medicine must always be taken exactly as directed by the physician. If in doubt, consult the physician or pharmacist. This medicine is used in adults and in children aged at least 1 year.

The recommended starting dose for adult patients with chronic phase chronic myeloid leukemia is 100 mg once daily.
The recommended starting dose for adult patients with accelerated phase or blast phase chronic myeloid leukemia, or with Philadelphia chromosome-positive acute lymphoblastic leukemia, is 140 mg once daily.
Dosing in children with chronic phase chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia is based on body weight.

The medicine is administered orally once daily. The use of Dasatinib Sandoz tablets is not recommended in patients with body weight below 10 kg. For patients with body weight below 10 kg and for patients who cannot swallow tablets, an oral suspension powder may be available. When switching between formulations (i.e., tablets and oral suspension powder), the dose may change; therefore, one formulation must not be substituted for the other.

The physician determines the appropriate formulation and dose for the patient based on body weight, adverse reactions, and response to treatment. The following table shows the recommended starting dose of Dasatinib Sandoz based on body weight:

It is not recommended to administer tablets to patients with body weight below 10 kg; for these patients, an oral suspension powder may be available.
Dosage recommendations for Dasatinib Sandoz in children under 1 year of age have not been established.
Depending on the patient's response to treatment, the doctor may recommend taking a higher or lower dose, or even temporarily interrupting treatment. To achieve higher or lower doses, it may be necessary to use a combination of tablets with different strengths.
Tablets may be available in calendar packs. These are blister packs marked with days of the week. Arrows indicate the next tablet to be taken according to the prescribed treatment schedule.
How to use Dasatinib Sandoz
Tablets should be taken every day at the same time. Tablets must be swallowed whole, without crushing, breaking, or chewing. Do not take a fragmented tablet. If a tablet is crushed, broken, chewed, or fragmented, it cannot be ensured that the correct dose of the drug has been administered. Dasatinib Sandoz can be taken with food or independently of meals.
Special instructions for handling Dasatinib Sandoz tablets
Breaking Dasatinib Sandoz tablets is unlikely, but if it occurs, individuals other than the patient should wear disposable gloves when handling the tablets.
How long to take Dasatinib Sandoz
Dasatinib Sandoz should be taken daily until your doctor advises stopping the treatment. Make sure to continue taking the medicine for as long as your doctor has instructed.
Taking more Dasatinib Sandoz than recommended
If too many tablets are accidentally taken, seek medical advice immediately. Medical assistance may be required.
Missing a dose of Dasatinib Sandoz
Do not take a double dose to make up for a missed tablet. Take the next dose at the usual time.
If you have any further questions regarding the use of this medicine, consult your doctor or pharmacist.

4. Possible adverse effects

Like all medicines, this medicine can cause adverse effects, although not everyone will experience them.
Symptoms which may indicate a serious adverse effect:

• chest pain, difficulty breathing, cough and fainting
• unexpected bleeding or bruising without prior injury
• blood in vomit, faeces or urine, black/tarry stools
• signs of infection, such as fever, severe chills
• fever, mouth or throat pain, development of blisters or peeling of the skin and (or) mucous membranes
  If any of the symptoms listed above occur, immediately contact a doctor.

Very common adverse effects ( may affect more than 1 in 10 people )

• Infections (including bacterial, viral and fungal infections)
• Heart and lungs: shortness of breath
• Gastrointestinal disorders: diarrhoea, nausea or vomiting
• Skin, hair, eyes, general symptoms: skin rash, fever, facial swelling, swelling of hands and feet, headache, feeling of fatigue or weakness, bleeding
• Pain: muscle pain (during or after treatment), abdominal pain
• Test results: low platelet count, low white blood cell count (neutropenia), anaemia, fluid around the lungs

Common adverse effects ( may affect less than 1 in 10 people )

• Infections: pneumonia, herpes virus infection (including cytomegalovirus - CMV),
  upper respiratory tract infection, severe blood or tissue infection (including not uncommon
  cases resulting in death)

• Heart and lungs: palpitations, irregular heartbeat, congestive heart failure, weakening of the heart muscle, high blood pressure in the lungs, cough

• Gastrointestinal disorders: appetite disturbances, taste disturbances, bloating or abdominal distension, inflammation of the large intestine, constipation, heartburn, mouth ulcers, weight gain, weight loss, inflammation of the stomach lining

• Skin, hair, eyes, general symptoms: tingling of the skin, itching, dry skin, acne, skin inflammation, persistent ringing in the ears, hair loss, excessive sweating, vision disturbances (including double vision and visual disturbances), dry eyes, bruising, depression, insomnia, sudden reddening of the skin, dizziness, injuries (bruises), loss of appetite, drowsiness, generalized swelling

• Pain: joint pain, muscle weakness, chest pain, pain in hands and feet, chills, muscle and joint stiffness, muscle cramps

• Test results: fluid around the heart, fluid in the lungs, heart rhythm disturbances, neutropenic fever, gastrointestinal bleeding, high levels of uric acid in the blood

Uncommon adverse effects ( may affect less than 1 in 100 people )

• Heart and lungs: heart attack (including fatal cases), inflammation of the lining (fibrous sac) around the heart, irregular heart function, chest pain due to reduced blood flow to the heart (angina), low blood pressure, narrowing of the airways which may cause breathing difficulties, asthma, increased blood pressure in the arteries (blood vessels) in the lungs
• Gastrointestinal disorders: pancreatitis, peptic ulcer, oesophagitis, abdominal swelling, anal fissure, difficulty swallowing, gallbladder inflammation, obstruction of bile ducts, gastro-oesophageal reflux (a condition in which acid and stomach contents flow back from the stomach into the oesophagus)
• Skin, hair, eyes, general symptoms: allergic reaction, including formation of tender, red nodules on the skin (erythema nodosum), restlessness, confusion, mood changes, decreased libido, fainting, tremor, eye inflammation causing redness or pain, skin disease characterized by tender, red blisters with sudden onset of fever and increased white blood cell count (neutrophilic dermatosis), hearing loss, light sensitivity, worsening of vision, increased tearing, skin pigmentation disorders, inflammation of subcutaneous fat tissue, skin ulceration, blistering of the skin, nail disorders, hair disorders, hand-foot syndrome, kidney failure, frequent urination, breast enlargement in men, menstrual disorders, general weakness and discomfort, hypothyroidism, balance disorders while walking, bone necrosis (a condition in which reduced blood flow to the bone leads to loss of bone tissue and bone death), arthritis, localized skin swelling
• Pain: vein inflammation which may cause redness, tenderness and swelling, tendon inflammation
• Brain: memory loss
• Test results: abnormal blood test results and possible kidney function disturbances due to tumour breakdown products (tumour lysis syndrome), low albumin levels in the blood, low lymphocyte count (a type of white blood cell) in the blood, high cholesterol levels in the blood, swollen lymph nodes, bleeding within the brain, irregular electrical activity of the heart, enlargement of the heart muscle, liver inflammation, presence of protein in the urine, increased creatine kinase activity (an enzyme mainly present in the heart, brain and skeletal muscles), increased troponin levels (a protein mainly present in cardiac and skeletal muscles), increased gamma-glutamyl transferase activity (an enzyme mainly present in the liver), milky fluid around the lungs (chylous effusion)

Rare adverse effects ( may affect less than 1 in 1000 people )

• Heart and lungs: enlargement of the right ventricle of the heart, myocarditis (inflammation of the heart muscle), syndrome of symptoms caused by blocked blood flow to the heart muscle (acute coronary syndrome), cardiac arrest (cessation of blood flow from the heart), ischaemic heart disease,
  inflammation of the tissue covering the heart and lungs, blood clot formation, presence of blood clots
  in the lungs

• Gastrointestinal disorders: loss of nutrients from the gastrointestinal tract, such as protein, intestinal obstruction, anal fistula (abnormal formation of a channel between the anus and surrounding skin), kidney function disorders, diabetes

• Skin, hair, eyes, general symptoms: seizures, optic neuritis which may cause complete or partial loss of vision, presence of blue-purple spots on the skin, abnormal overactivity of the thyroid gland, thyroid inflammation, ataxia (a condition associated with lack of muscular coordination), difficulty walking, miscarriage, inflammation of skin vessels, skin fibrosis

• Brain: stroke, transient episode of neurological disturbances due to lack of blood flow, facial nerve paralysis, dementia

• Immune system: severe allergic reaction

• Musculoskeletal and connective tissue: delayed healing of rounded ends of bones forming joints (epiphyses); slowed or delayed growth

Other reported adverse effects (frequency unknown – cannot be estimated from available data ):

• pneumonia
• bleeding from the stomach or intestines, which may lead to death
• reactivation of hepatitis B virus infection in patients with a past history of such infection
• reaction with fever, blistering of the skin and ulceration of mucous membranes
• kidney disease with symptoms including swelling and abnormal diagnostic test results, such as presence of protein in urine and low protein levels in blood
• blood vessel damage known as thrombotic microangiopathy, including reduced number of red blood cells, reduced platelet count and blood clot formation.

During treatment, your doctor will monitor for some of these adverse effects.
Reporting of adverse effects
If any adverse effects occur, including any not listed in this leaflet, tell your doctor, pharmacist or nurse. Adverse effects can be reported directly to the Department of Monitoring Adverse Drug Reactions of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products: Al. Jerozolimskie 181C, 02-222 Warsaw
tel.: + 48 22 49 21 301, fax: + 48 22 49 21 309, website: https://smz.ezdrowie.gov.pl
Adverse effects can also be reported to the marketing authorization holder.
Reporting adverse effects helps provide more information on the safety of this medicine.

5. How to store Dasatinib Sandoz

Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the bottle, blister pack,
and cardboard box after "EXP". The expiry date refers to the last day of the stated month.
No special storage conditions are required for this medicine.
Medicines must not be disposed of via the sewage system or household waste.
Ask your pharmacist how to dispose of medicines no longer required.
These measures will help protect the environment.

6. Contents of the pack and other information

What Dasatinib Sandoz contains

• The active substance is dasatinib. Each coated tablet contains 140 mg of dasatinib.
• The other ingredients are: microcrystalline cellulose, lactose monohydrate, sodium croscarmellose, hydroxypropylcellulose, magnesium stearate.
  Coating: polyvinyl alcohol, titanium dioxide (E 171), talc, glycerol monostearate, sodium lauryl sulfate.

What Dasatinib Sandoz looks like and contents of the pack
White or almost white, round, biconvex coated tablets with a diameter of 11.8 mm,
imprinted with the number "140" on one side and smooth on the other side.
The coated tablets are packed in single-dose blisters made of Aluminium/OPA/Aluminium/PVC foil and placed in a cardboard box.
Pack sizes:
The cardboard box contains 30 x 1 coated tablets in single-dose blisters.

Marketing Authorisation Holder
Sandoz GmbH
Biochemiestrasse 10
6250 Kundl, Austria

Manufacturer
Lek Pharmaceuticals d.d.
Verovškova 57
1526 Ljubljana, Slovenia
Remedica Ltd.
Aharnon Street, Limassol Industrial Estate
3056 Limassol, Cyprus

For further information about this medicinal product and its trade names in the European Economic Area countries, please contact:
Sandoz Polska Sp. z o.o.
ul. Domaniewska 50 C
02-672 Warsaw
tel. 22 209 70 00

Company logo